Multifunctional Scaffold for Osteoporotic Pathophysiological Microenvironment Improvement and Vascularized Bone Defect Regeneration

Adv Healthc Mater. 2023 Jun;12(15):e2203099. doi: 10.1002/adhm.202203099. Epub 2023 Feb 25.

Abstract

Osteoporosis is a degenerative bone disease resulting from bone homeostasis imbalance regulated by osteoblasts and osteoclasts. Treating osteoporotic bone defects tends to be more difficult due to suppressed osteogenic differentiation, hyperactive osteoclastogenesis, and impaired angiogenesis. Hence, a drug carrier system composed of gelatin-coated hollow mesoporous silica nanoparticles (HMSNs/GM) loaded with pro-osteogenic parathyroid (PTH) and anti-osteoclastogenic alendronate (ALN) is constructed and compounded into calcium magnesium phosphate cement (MCPC). The spatial-temporal release of ions and drugs, controllable degradation rate, and abundant pore structure of MCPC composites enhance osteoporotic bone regeneration in ovariectomized rats by accelerating vascularization, promoting osteogenic differentiation and mineralization, and inhibiting osteoclastogenesis and bone resorption. The MCPC/HMSNs@ALN-PTH/GM demonstrates a synergistic threefold effect on osteogenesis, osteoclastogenesis, and angiogenesis. It improves the osteoporotic pathophysiological microenvironment and promotes osteoporotic vascularized bone defect regeneration, holding huge potential for other functional biomaterials design and clinical management.

Keywords: bone homeostasis; calcium magnesium phosphate cements; osteoclastogenesis; osteoporotic bone defects; vascularized bone regeneration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alendronate / chemistry
  • Alendronate / pharmacology
  • Animals
  • Biocompatible Materials / pharmacology
  • Bone Regeneration / physiology
  • Osteoclasts
  • Osteogenesis*
  • Osteoporosis* / drug therapy
  • Rats

Substances

  • Biocompatible Materials
  • Alendronate